aspiration pressure necessary to draw a cell into a small 3.311m pipette (as a model of a capillary) was generally higher in the neonate, but this was due to the cells being larger. When the experiments were done on cells of the same MCV, the neonatal ones required a slightly lower pressure. Hence he concluded that the two types of cells do show small but significant differences in their membrane properties and these, he hypothesized, may be part of the reason for the shorter lifetime of neonatal cells.
A related paper by Dr T Kamalati (Kings College Hospital Medical School, London) concerned the use of electron spin resonance to study the molecular fluidity of neonatal erythrocyte membranes. The probe she used was 5 doxy l-stearic acid, which gives information on the freedom of movement of the lipids in the membrane. It was clear that in the neonate this form of fluidity is increased compared to adults. What is, however, not yet clear is the relationship of such molecular fluidity data to mechanical data such as reported by Professor Linderkamp. Nevertheless, it is interesting that she has also found decreased erythrocyte membrane fluidity in severe peripheral vascular disease patients where evidence exists for mechanical deformability to be decreased'.
Dr M W Rampling returned to the platform to talk more generally about neonatal haemorheology. He showed that usually the viscosity of neonatal blood was reduced compared to that of the adult. In part this was due to the lower plasma viscosity in the newborn due to lowered plasma protein concentrations, but there was a greater reduction at low shear rate than this alone would explain. The reason appeared to relate to the lower level of rouleaux formation found in the neonate. He presented data showing that this was not the result of differences in the red cells but rather due to plasma differences. Furthermore, while the lowered fibrinogen level common in the newborn was partly responsible, it did not provide a full explanation. He suggested that the answer might lie in the presence of the fetal variant of fibrinogen in the neonatal plasma which, because of its higher sialic acid content, would tend to interact less with the erythrocyte.
Other sessions on obstetric haemorheology and free communications completed a stimulating and enjoyable two days. However, what was particularly gratifying about this meeting was the presence of a large number of participants from the Continent. Considerable effort had been made to entice European haemorheologists to this British meeting in the hope of breaking down the insularity of the national haemorheology groups. This appears to have been successful, as joint meetings between the British and European groups are now being planned. At this meeting of the RSM's Section of Pathology, the regulation ofhaemopoietic stem cells and growth factors regulating various cell lines were described, and the role of oncogenes, platelet-derived growth factor and nerve growth factor in growth regulation was discussed.
MWRampling

Haemopoietic growth factors
Professor A J Barrett (Charing Cross & Westminster Medical School, London) said that the study of blood cell development from the haemopoietic stem cell progenitor provides an insight into the fundamental organization of cell maturation and division in a complex tissue. In recent years the hierarchy of blood cell development has been reasonably well defined. Such research has been made possible by in vitro culture techniques and use of experimental animals. Regulation ofhaemopoiesis is controlled by several growth factors. Erythropoietin, the regulator oflate erythropoietic development, was the first to be defined. Subsequently, Metcalfdescribed an assay for progenitors of granulocytes and monocytes whose growth was dependent on a 'colony-stimulating factor' derived from mature leukocytes. Since then a number of colony-stimulating factors have been defined. Thrombopoietins regulating megakaryocyte growth have also been described but have not been characterized in detail. In addition, growth factors for early stem cell development and maturation are known, but specific inhibitors and stimulators are believed to regulate pluripotent stem cell proliferation. Further development and maturation is regulated by a pluripoietin (interleukin 3). The use of molecular cloning techniques has allowed the nature of growth factors and their function to be characterized in more detail. Granulocyte-monocyte colony-stimulating factor (GM·CSF) has been intensively investigated by Metcalf and others in Australia. Several CSFs exist with different activities, stimulating either monocytes, granulocytes or both. CSF is specific to granu-Report of meeting of Section of Pathology, 1 April 1986 0141-0768/87/ 090591.03/$02.00/0 It) 1987
The Royal Society of Medicine lopoietic cells and shows partial species specificity. It is needed constantly during growth and maturation of neutrophils and monocytes and is also required for normal neutrophil function. CSF stimulates cells from GO to G1 phase of the cell cycle and shortens the cell cycle time. Antibodies to CSF have been used to identify surface receptors for the molecule which binds the growth factor and subsequently internalizes it. Thus CSF is used up during granulopoiesis. The intracellular events following CSF-receptor binding are not well known but it is believed that protein kinase C is activated during the process of stimulation which in turn activates DNA synthesis and cell division. Only 10% CSF surface receptors are required to be bound to CSF to initiate 50% of the maximum proliferation.
Despite these impressive properties in vitro, a clear physiological role for CSF has not been demonstrated. In favour of the importance of CSF in granulopoiesis is the observation that congenital neutropenia in the grey collie dog is accompanied by CSF level fluctuations which correlate inversely with the peaks and troughs of neutropenia. Some neoplasms associated with a massive leukocytosis in man have been shown to produce large amounts of ectopic CSF. However, the administration ofCSF to mice does not result in a sustained neutrophilleukocytosis, nor does the administration of antibody to CSF cause neutropenia. The role of this molecule in granulopoietic regulation in vivo therefore remains enigmatic.
Further developments in understanding haemopoietic growth factors have come from the development of cuIture systems such as the Dexter suspension culture. Such cultures maintain haemopoiesis over several weeks in man and indefinitely in mice. Granulopoiesis in these cultures occurs in the absence of detectable CSF in the medium, but it requires close cell-cell contact between macrophages, fibroblasts and stem cells. This is shown to be necessary for exchange of CSF from the microenvironmental cells to the GM colony-forming cell.
Haemopoietic stem cell regulation Dr B I Lord (Christie Hospital & Holt Radium Institute, Manchester) stated that the fundamental unit of blood production is the pluripotent haemopoietic stem cell. It is this cell, measured as the spleen colony-forming unit or CFU·S, which has the capacity to repopulate the entire haemopoietic tissue and, as such, it requires careful regulation to maintain its integrity as a stem cell and to control its proliferation and differentiation.
Proliferation is governed by specific inhibitory and stimulatory factors which are generated by subpopulations of bone marrow macrophages. They act in concert as a proliferation 'on/off' switch depending on the requirements for growth of the population. In addition, there is interaction between the production of inhibitor and stimulator whereby the production of one inhibits the production of the other. This means that the CFU-S population in some way signals its presence to its regulatory microenvironment such that an integrated negative feedback loop is established, i.e. a reduced stem cell population gives only a weak signal and in these circumstances proliferation stimulator is promoted. When the population returns to normal the increased feedback signal reinstates inhibitor production.
Experiments where the size of stem cell populations (purified by a fluorescent activated cell sorter) were varied independently from the other regulatory bone marrow cells confirm the existence of such a feedback regulation.
A newly defined growth factor, interleukin 3 (lL-3), derived from spleen cells and other sources, is vital to the growth of various factor-dependent stem cell lines. Unlike the inhibitor and stimulator of pluripotent stem cells, IL-3 acts on a wide variety of haemopoietic precursors. Its physiological role has not been defined. Recently, however, the availability of highly purified recombinant IL-3 has enabled study of its effects in vivo. Very low doses oflL-3 administered to mice either as a single injection or by continuous infusion for up to 7 days caused a six-fold rise in spleen CFU·S with a slight reduction in bone marrow CFU-S, possibly due to splenic migration.
It appears, therefore, that IL-3 can be used as a potent in vivo growth modifier in haemopoietic tissue and has tremendous potential for manipulating the system. It is also interesting that the changes described are closely mimicked by endotoxin injections, and it is tempting to speculate that the effects of endotoxin on the haemopoietic system are mediated through the release of the short-range acting IL-3 molecule.
The factors or molecules discussed above are effecti ve in modifying growth and kinetic parameters of the haemopoietic stem cell. They are effecti ve in vivo and their physiological relevance and pharmacological significance are now being evaluated.
Oncogenes
Dr Peter Parker (Imperial Cancer Research Fund Laboratories, London) said that through a variety of approaches, researchers have discovered genes that are capable of transforming cells in culture. These socalled oncogenes have normal cellular counterparts. The transforming potential of these genes appears to be generated through aberrant expression, as seen with, for example, c-myc or through the expression of a mutated product, for example, the ras gene family. One of the central questions arising from these studies is 'What is the normal function of the genes and how are these functions converted to a transforming function?' Interestingly, progress in solving these problems has come from studies on the action of growth factors in the control of normal growth and differentiation.
The sequence of the heterodimeric protein plateletderived growth factorfor fibroblasts (PDGF) revealed that one of the two polypeptide chains is the normal cellular homologue of the transforming gene v-eis. Thus it appears that the virus carrying the v-eis gene had picked up the cellular gene coding for a chain of PDGF and, more importantly, that the expression of this gene in certain cells was capable of allowing these cells to proliferate in an uncontrolled manner. This endogenous production and response to growth factors represents autocrine stimulation and is clearly relevant to human cancer since there is, for example, very good evidence that certain small cell carcinomas of the lung produce and respond to the mitogenic neuropeptide bombesin.
PDGF lies at the top of a cellular control hierarchy that runs from growth factor, through specific receptors via transducing pathways within the cell to elicit biological responses. The implication of the PDGF story is that this autocrine loop turns on these pathways constitutively; this begs the question, 'Do other oncogenes follow similar strategies in activating this normal cellular control hierarchy?'
The elucidation of the sequence of the epidermal growth factor receptor (EGF-R) has revealed that a truncated version ofthis transmembrane polypeptide has been picked up by an avian virus to produce the v-erb B transforming gene. While no formal proof exists, this implies that this truncated polypeptide functions as an activated growth factor receptor (i.e. as a ligand bound receptor) in an uncontrolled manner. Similarly, there are recent data indicating that CSF-1 receptor is the cellular homologue of the v-fms transforming protein. Thus oncogenes may undermine the function of proteins that are normally involved in controlling cell proliferation.
It is not clear how far down the normal growth control hierarchy that this strategy for transformation occurs. It is clear, however, that post-receptor pathways are very complex and elucidation of these transducing pathways will be of great interest in terms of our understanding of uncontrolled proliferation.
Nerve growth factor
Professor Charles Vernon (University College Hospital, London) commented that the existence of a factor essential for nerve outgrowth in chick embryos has been known for many years. The factor is a glycoprotein with a molecular weight below Journal of the Royal Society of Medicine Volume 80 September 1987 593 100000. Interestingly, in parallel to the action of CSF, it is essential not only for the growth but also continued survival of neural tissue. Its precise structure and physiological role remain largely undefined.
Conclusions
Haemopoiesis, in particular, has provided a rich field of investigation into the nature and properties of growth factors. These studies point to the possibility that specific growth factors are necessary for a number of functions, including cell survival as well as cell proliferation and development. Their specificity and mode of action are linked directly to the presence of specific surface receptors on the target cell, and their mechanism of action within the cell cytoplasm and nucleus may therefore share a final common pathway. Thus, investigation into the mode of action of specific growth factors such as CSF may provide fundamental information relevant to the action of other growth factors. In addition, our understanding of physiological growth factors has shed light on the very similar role that oncogenes may play in causing abnormal growth in malignant processes.
AJBarrett
Immediate Past President Section of Pathology (Accepted 9 September 1986) New concepts in vaccination Keywords: vaccines, viruses, recombinants, adjuvants, immune system The November 1986 meeting of the Section of Comparative Medicine had as its theme, 'New concepts in vaccination'. The first speaker, Dr A J Beale (Wellcome Biotechnology), gave a brief summary of old and new ideas about protective vaccination. Dr Edward Jenner made the first semi-scientific attempt to develop a vaccine with his development of the cowpox vaccine and the idea of using live attenuated organisms as vaccines was formally introduced by Louis Pasteur. Dr Glenny (Wellcome) had been a further pioneer in the history of vaccine production by highlighting the difference between the primary and secondary immune response, introducing formalin for toxoiding diphtheria and tetanus toxins and to preserve immunogenicity, and very importantly, by introducing aluminium salts as immunostimulating adjuvants. Dr Beale also mentioned the survey of 1000 families carried out in Newcastle-Upon-Tyne shortly after the Second World War, in which children were followed up from birth for 20 years in an effort to study the pattern of infectious diseases such as whooping cough and to show the immunizing effect of these infections in the general population. Professor J W Almond (Reading University) spoke of his studies of the neurovirulence of polio-viruses and the prospects for new vaccines. Although the incidence of poliomyelitis had declined rapidly after the introduction of,first, the inactivated vaccine (Salk), and then the live attenuated oral vaccine (Sabin), WHO still reports an incidence of at least 500000 cases of polio a year, thus highlighting the need for a new and more effective vaccine. Work has concentrated on the serotype 3 poliovirus, which is most often implicated in cases of paralysis in vaccinees. The neurovirulent parent strain (P3/ Leon/37) was isolated from the brain and spinal cord of a fatal case of polio. After passage through monkey tissue, the Leon progenitor and then the P3/Sabin vaccine was obtained. A revertant strain P3/119 had a high virulence score, as did the Leon progenitor. The Sabin vaccine strain had a very low virulence score, it was easy to administer to large populations and was thus cost-effective and the most widely used polio vaccine. A study on passage in man of the Sabin vaccine strain had revealed excretion ofa virus with a greatly increased histological lesion score, indicating rapid selection and/or reversion for a neurovirulent strain by growth in the human gut. A series of recombinants has been found in the pathway between the parent P3/Leon/37 and P3/Sabin strains. Two mutations at base positions 472 and 2034 contribute to attentuation. Similarly, changes at base position 480 (next position to 472 in serotype 3) have been found to occur during the production of the type 1 vaccine strain (Sabin 1) from its virulent progenitor Mahoney. New approaches to the development of a more effective vaccine have been facilitated by 
